Drug Profile
Olesoxime - Roche
Alternative Names: Cholest-4-en-3-one,-oxime; Cholest-4-en-3-ylidenehydroxylamine; RG-6083; TRO-19622Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Trophos
- Developer Roche; Trophos
- Class Analgesics; Cholestenones; Hepatoprotectants; Neuroprotectants; Oximes; Small molecules
- Mechanism of Action Mitochondrial permeability transition pore modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Diabetic neuropathies; Huntington's disease; Multiple sclerosis; Neuropathic pain; Non-alcoholic steatohepatitis; Spinal muscular atrophy
Most Recent Events
- 26 Jul 2018 Discontinued - Phase-II/III for Spinal muscular atrophy (In adolescents, In children, In adults) in Poland, France, Netherlands, Germany (PO) (Roche pipeline, July 2018)
- 26 Jul 2018 Discontinued - Phase-II for Multiple sclerosis in France (PO) (Roche pipeline, July 2018)
- 26 Jul 2018 Discontinued - Phase-II/III for Spinal muscular atrophy (In adolescents, In children, In adults) in Belgium (PO) (Roche pipeline, July 2018)